The importance of knowledge valuation for knowledge networks and markets

This chapter discusses future trends in the valuation of biotechnology and pharmaceutical assets as well as the companies that hold them, the development of new forms of financing health research, and how these developments impact on and may be influenced by knowledge networks and markets (KNMs) and new models of knowledge management. Several open questions remain, including: will improved valuation of biomedical firms and their assets also entail a better understanding and use of such intellectual assets and, if so, how might KNMs facilitate progress? And, can KNMs be constructed and operated so that they successfully reduce financial risk to their participants as well as increasing efficiency of innovation through collective action?